A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Clinical trial NCT05145413 · COMPLETED
Trial details
- NCT number
- NCT05145413
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-12
- Primary completion
- 2025-03-19
- Enrollment
- 396
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.